# Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer

> **NCT07562503** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 340 (estimated)

## Conditions studied

- ctDNA
- Colorectal Cancer
- Chemotherapy

## Interventions

- **DRUG:** CAPEOX regimen
- **DRUG:** CAPEOX regimen

## Key facts

- **NCT ID:** NCT07562503
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07562503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07562503, "Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07562503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*